Following the succession plan initiated more than a year ago, when Eduardo Sanchiz expressed his wish to devote more time to his family and other interests, the board of directors of Spain’s largest pharma firm Almirall has approved the appointment of Peter Guenter as chief executive effective October 1, 2017.
Mr Guenter joins Almirall from French pharma major Sanofi, where he has worked for the last 22 years, most recently as executive vice president diabetes and cardiovascular global business unit. During his tenure at Sanofi, he held many senior positions including VP Eastern Europe and Northern Europe, VP business management. Before joining Sanofi, he held different positions in sales and marketing at Smith Kline and Ciba Geigy.
“I am particularly satisfied that we have been able to attract Peter Guenter to Almirall. He is a truly global leader and brings a wealth of experience in US, Europe and Emerging Markets. I am convinced he will bring what is needed to develop Almirall to the next level,” said Jorge Gallardo, chairman of Almirall.
“I am excited and eager to join Almirall as CEO. The company has a clearly defined and sound strategy and has the determination and means to execute this strategy, putting the patients and customers at the center of everything we do. Together with my team, I am convinced we will be able to fully unlock the value of Almirall,” said Mr Guenter.
Eduardo Sanchiz has been with Almirall for 13 years and was appointed CEO in July 2011. He will transition with Mr Guenter during the month of September.
Source: The Pharma Letter
Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]
Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]
Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]